IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney's Docket No. 002010-746

CH CENTER 1600/2901 In re Patent Application of Group Art Unit: 1644 S. A. RUBIN et al. Examiner: Phillip Gambel Application No.: 09/010,377 Confirmation No.: 8602 Filed: January 21, 1998

TREATMENT OF VIRAL For: **ENCEPHALITIS BY AGENTS**

BLOCKING ALPHA-VLA-4 INTEGRIN FUNCTION

INFORMATION DISCLOSURE STATEMENT TRANSMITTAL LETTER

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Enclosed is an Information Disclosure Statement and accompanying form PTO-1449 for the above-identified patent application.

[]	No additional fee for s	submission of an IDS is required.		
[]	The fee of \$180.00 (1806) as set forth in 37 C.F.R. § 1.17(p) is also enclosed.			
[]	A statement under 37 C.F.R. § 1.97(e) is also enclosed.			
[X]	A statement under 37 C.F.R. § 1.97(e), and the fee of \$180.00 (1806) as set forth in 37 C.F.R. § 1.17(p) are also enclosed.			
[]	Charge \$	to Deposit Account No. 02-4800 for the fee due.		

[] A check in the amount of \$_180.00_\ is enclosed for the fee due.

The Director is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

Date: May 28, 2003

P.O. Box 1404

[X]

Alexandria, Virginia 22313-1404

(703) 836-6620

Registration No. 48,036



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of)		RECE
S. A. RUBIN et al.)	Group Art Unit: 1644	RECEIVED
Application No.: 09/010,377)	Examiner: Phillip Gambel	JUN 0 2 2003
Filed: January 21, 1998))	Confirmation No.: 8602	TECH CENTER 1600/2900
For: TREATMENT OF VIRAL ENCEPHALITIS BY AGENTS BLOCKING ALPHA-VLA-4 INTEGRIN FUNCTION)))		

SECOND INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, Applicants hereby submit information in conformance with 37 C.F.R. §§ 1.97 and 1.98. Pursuant to 37 C.F.R. § 1.98, a copy of each of the documents cited is enclosed.

The documents are being submitted after the close of prosecution but prior to, or concurrently with, the payment of the issue fee, therefore under 37 C.F.R. § 1.97(d) a statement and the fee set forth in 37 C.F.R. § 1.17(p) are enclosed.

A fee in the amount of \$180.00 (1806) as set forth in 37 C.F.R. § 1.17(p) is enclosed.

I, the undersigned, hereby state that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.

05/29/2003 SZEHDIE1 00000042 09010377

01 FC:1806

180.00 GP

Information Disclosure Statement Application No. 09/010,377 Attorney's Docket No. 002010-746 Page 2

To assist the Examiner, the documents are listed on the attached form PTO-1449. It is respectfully requested that an Examiner-initialed copy of this form be returned to the undersigned.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

Date: May 28, 2003

y: _____

Registration No. 48,036

P.O. Box 1404 Alexandria, Virginia 22313-1404 (703) 836-6620

SHEET <u>1</u> OF 1

Substitute for forms 1449A/PTO & 1449B/PTO

ATTORNEY'S DKT NO. 002010-746 APPLICATION NO. 09/010,377

APPLICANT
S. A. RUBIN et al.

Filing Date GROUP
January 21, 1998 1644

SECOND INFORMATION DISCLOSURE STATEMENT BY APPLICANT

1644 **U.S. PATENT DOCUMENTS** Issue/Publication Examiner **Document** Kind Code Name of Patentee or Applicant Initials Number Date (if known) of Cited Document (MM-DD-YYYY) FOREIGN PATENT DOCUMENTS Examiner Document Kind Code Date of Publication Translation Initials Number (if known) Country (MM-DD-YYYY) Yes WO 93/15764 PCT 08-19-1993 WO 94/16094 A2 PCT 07-21-1994

Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. Olivier J.P. Léger et al. "Humanization of a mouse antibody against human alpha-4 integrin: A potential therapeutic for the treatment of multiple sclerosis," Human Antibodies, vol. 8(1), pp. 3-16 (1997). Frank KOLBINGER et al., "Humanization of a mouse anti-human IgE antibody: a potential therapeutic for IgE-mediated allergies," Protein Engineering, vol. 6(8), pp. 971-980 (1993).

C			
Examiner		Date	
Signature			1
EYAMINED: I-	High if your	Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.